glp-1 health risks INFOGRAPHIC: The Hidden of Weight Loss Medications GLP-1 Agonists In Obesity

Women experience gastrointestinal side effects at approximately 2.5 times the rate of men on equivalent retatrutide doses

What Retatrutide Dose Produced The Most Weight Loss In Studies

Compared with traditional GLP-1 receptor agonists such as Semaglutide and Tirzepatide , Retatrutide performs better in weight management and insulin sensitivity

Regular bloodwork every three to six months helps monitor metabolic improvements and catch any unexpected changes early

As of 2025, retatrutide is still in Phase 3 clinical trials

Approximately 70% of American adults are obese or overweight, a severe health issue associated with heart disease, stroke, and diabetes, linked to an increased risk of certain types of cancer